264,562 Shares in Alphatec Holdings, Inc. (NASDAQ:ATEC) Acquired by Altium Capital Management LLC

Altium Capital Management LLC acquired a new stake in Alphatec Holdings, Inc. (NASDAQ:ATEC) during the 4th quarter, HoldingsChannel reports. The firm acquired 264,562 shares of the medical technology company’s stock, valued at approximately $2,429,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Barclays PLC increased its stake in shares of Alphatec by 362.3% in the third quarter. Barclays PLC now owns 170,546 shares of the medical technology company’s stock worth $948,000 after acquiring an additional 133,653 shares during the last quarter. Franklin Resources Inc. grew its stake in Alphatec by 299.3% in the third quarter. Franklin Resources Inc. now owns 64,450 shares of the medical technology company’s stock valued at $343,000 after purchasing an additional 48,308 shares in the last quarter. State Street Corp increased its position in Alphatec by 10.1% in the 3rd quarter. State Street Corp now owns 3,138,960 shares of the medical technology company’s stock worth $17,453,000 after purchasing an additional 287,350 shares during the last quarter. Congress Asset Management Co. raised its stake in shares of Alphatec by 235.4% during the 4th quarter. Congress Asset Management Co. now owns 434,966 shares of the medical technology company’s stock worth $3,993,000 after purchasing an additional 305,296 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Alphatec by 3.0% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 201,672 shares of the medical technology company’s stock valued at $1,121,000 after buying an additional 5,883 shares during the last quarter. Hedge funds and other institutional investors own 66.35% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. Piper Sandler increased their price objective on Alphatec from $12.00 to $13.00 and gave the stock an “overweight” rating in a report on Thursday, February 27th. StockNews.com upgraded shares of Alphatec from a “sell” rating to a “hold” rating in a research note on Friday, February 28th. Barclays lifted their price objective on shares of Alphatec from $20.00 to $21.00 and gave the company an “overweight” rating in a research note on Wednesday, January 22nd. Needham & Company LLC reissued a “buy” rating and set a $16.00 target price on shares of Alphatec in a research report on Thursday, February 27th. Finally, HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of Alphatec in a report on Monday. Two equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, Alphatec has an average rating of “Moderate Buy” and an average target price of $17.67.

Insider Transactions at Alphatec

In related news, CEO Patrick Miles sold 6,687 shares of Alphatec stock in a transaction dated Tuesday, January 21st. The stock was sold at an average price of $12.00, for a total transaction of $80,244.00. Following the sale, the chief executive officer now directly owns 5,501,715 shares of the company’s stock, valued at $66,020,580. This trade represents a 0.12 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP David Sponsel sold 36,256 shares of the business’s stock in a transaction dated Monday, February 3rd. The shares were sold at an average price of $11.42, for a total value of $414,043.52. Following the transaction, the executive vice president now owns 735,074 shares in the company, valued at $8,394,545.08. This represents a 4.70 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 278,800 shares of company stock worth $3,201,469. Insiders own 22.80% of the company’s stock.

Alphatec Stock Up 3.2 %

ATEC stock opened at $10.56 on Friday. The stock has a market capitalization of $1.52 billion, a price-to-earnings ratio of -8.25 and a beta of 1.20. The company has a 50-day moving average of $10.38 and a two-hundred day moving average of $9.42. Alphatec Holdings, Inc. has a 52-week low of $4.88 and a 52-week high of $13.79. The company has a debt-to-equity ratio of 30.21, a current ratio of 2.32 and a quick ratio of 1.15.

Alphatec (NASDAQ:ATEC) last announced its earnings results on Wednesday, February 26th. The medical technology company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.04). The business had revenue of $176.79 million for the quarter, compared to the consensus estimate of $172.74 million. Alphatec had a negative net margin of 31.06% and a negative return on equity of 541.39%. As a group, equities research analysts anticipate that Alphatec Holdings, Inc. will post -1.08 EPS for the current year.

Alphatec Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.